Carboplatin—gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration

Abstract

Carboplatin—gemcitabine doublet is an important therapeutic option for patients with both previously treated and untreated ovarian cancer (OC). At the currently recommended dosing, its main toxicity is hematological, consisting of thrombocytopenia, neutropenia, including febrile neutropenia, and/or anemia. The use of platelet transfusions, G-CSF and/ or packed red blood cells is often necessary, in order to avoid treatment delays or omission of doses. We report here on the high efficacy of lower doses of gemcitabine at 750 mg/m² on days 1 and 8 in combination with carboplatin AUC = 4 on day 1, repeated in 21-day cycles, in a small series of patients with advanced/metastatic OC. Using the above dose regimen, durable complete remissions were achieved in all patients in our cohort within 9—12 weeks, with no growth factor support, and no transfusions of blood components being necessary. We believe that lowering the doses of both carboplatin and gemcitabine from the start of therapy would ensure their timely delivery and steady-state plasma drug levels. In conclusion, administration of carboplatin AUC = 4 and gemcitabine 750 mg/m² appears to be a safe and effective combination for the therapy of advanced/metastatic OC, with clinically tolerable hematological toxicity.

Keywords

gemcitabine carboplatin hematological toxicity ovarian cancer dose reduction

Get full access to this article

View all access options for this article.

References

Lorusso D. , Di Stefano A. , Fanfani F. , Scambia G. Role of gemcitabine in ovarian cancer treatment. Ann Oncol 2006; 17(5): 188-94.

Poveda A. Gemcitabine in patients with ovarian cancer. Cancer Treat Rev 2005; 31(4): S29-37.

Mutch DG Gemcitabine combination chemotherapy of ovarian cancer. Gynecol Oncol 2003; 90(2 Pt 2): S16-20.

Kose MF , Meydanli MM , Tulunay G. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma . Expert Rev Anticancer Ther 2006 ; 6(3): 437-43.

Kose MF , Sufliarsky J. , Beslija S. , Saip P. , Tulunay G. , Krejcy K. et al. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol Oncol 2005; 96(2): 374-80.

Tay SK , Ilanchadran A. , Tan TY First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study. BJOG 2006; 113(12): 1388-92.

Tassinari D. , Fochessati F. , Arcangeli V. , Sartori S. , Agostini V. , Fantini M. et al. Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial. Tumori 2004; 90(1): 54-9.

Laessig D. , Stemmler HJ , Vehling-Kaiser U. , Fasching PA , Melchert F. , Kolbl H. et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 2007 ; 73(5-6): 407-14.

Xiros N. , Papacostas P. , Economopoulos T. , Samelis G. , Efstathiou E. , Kastritis E. et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16(5): 773-9.

10.

Soo RA , Wang LZ , Tham LS , Yong WP , Boyer M. , Lim HL et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 2006; 17(7): 1128-33.

11.

Richardson DL , Backes FJ , Seamon LG , Zanagnolo V. , O’Malley DM , Cohn DE et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008; 111(3): 461-6.